Symphony Asset Management LLC decreased its position in shares of Agilent Technologies, Inc. (NYSE:A) by 2.8% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,089 shares of the medical research company’s stock after selling 178 shares during the quarter. Symphony Asset Management LLC’s holdings in Agilent Technologies were worth $361,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. AJO LP purchased a new stake in Agilent Technologies in the 2nd quarter worth $12,468,000. Coastline Trust Co lifted its stake in Agilent Technologies by 63.5% in the 2nd quarter. Coastline Trust Co now owns 8,560 shares of the medical research company’s stock worth $508,000 after purchasing an additional 3,325 shares in the last quarter. Financial Counselors Inc. lifted its stake in Agilent Technologies by 140.6% in the 2nd quarter. Financial Counselors Inc. now owns 28,237 shares of the medical research company’s stock worth $1,675,000 after purchasing an additional 16,500 shares in the last quarter. Commonwealth Bank of Australia lifted its stake in Agilent Technologies by 275.5% in the 2nd quarter. Commonwealth Bank of Australia now owns 20,899 shares of the medical research company’s stock worth $1,237,000 after purchasing an additional 15,334 shares in the last quarter. Finally, Old Mutual Global Investors UK Ltd. purchased a new stake in Agilent Technologies in the 2nd quarter worth $7,117,000.
In other news, CFO Didier Hirsch sold 1,200 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $66.00, for a total value of $79,200.00. Following the transaction, the chief financial officer now directly owns 164,202 shares of the company’s stock, valued at $10,837,332. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael R. Mcmullen sold 16,492 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $65.33, for a total transaction of $1,077,422.36. Following the completion of the transaction, the chief executive officer now directly owns 211,872 shares in the company, valued at $13,841,597.76. The disclosure for this sale can be found here. Over the last three months, insiders sold 155,165 shares of company stock worth $9,768,409.
Shares of Agilent Technologies, Inc. (A) opened at 65.96 on Friday. The company has a market capitalization of $21.23 billion, a P/E ratio of 34.02 and a beta of 1.30. The stock has a 50 day moving average of $62.40 and a 200-day moving average of $58.01. Agilent Technologies, Inc. has a 12-month low of $42.92 and a 12-month high of $66.42.
Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.07. The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. Agilent Technologies had a net margin of 14.36% and a return on equity of 16.95%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period last year, the firm posted $0.49 earnings per share. Equities research analysts forecast that Agilent Technologies, Inc. will post $2.32 EPS for the current year.
A has been the topic of several research analyst reports. Deutsche Bank AG reiterated a “buy” rating and issued a $66.00 price target on shares of Agilent Technologies in a research note on Thursday, June 22nd. Morgan Stanley boosted their price target on shares of Agilent Technologies from $65.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 24th. Jefferies Group LLC reiterated a “buy” rating and issued a $66.00 price target on shares of Agilent Technologies in a research note on Wednesday, August 9th. BTIG Research boosted their price target on shares of Agilent Technologies from $57.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, May 24th. Finally, BidaskClub cut shares of Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $63.91.
TRADEMARK VIOLATION NOTICE: This news story was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/09/16/symphony-asset-management-llc-has-361000-position-in-agilent-technologies-inc-a.html.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A).
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.